5 things to know about CRISPR and gene editing in the COVID era
Precision medicine is playing a key role in understanding COVID-19. Here's how gene testing and gene editing are accelerating the future of healthcare.
Dr. Trevor Martin is a scientist turned entrepreneur who founded Mammoth Biosciences to enable the next generation of CRISPR-based synthetic biology products to read and write the code of life. Mammoth's technology is democratizing diagnostics with a novel class of affordable, effective, and rapid CRISPR-enabled molecular tests that bring the power and accuracy of lab-based testing for any disease into an easy to use disposable paper format usable in the field and at home. The Mammoth platform for developing novel CRISPR systems has also created nano-sized CRISPR proteins that enable the future of in-vivo editing for therapies from rare diseases to cancer. His work has been featured in outlets including FiveThirtyEight and The Atlantic and in addition to many awards including an NSF Graduate Research Fellowship, he is featured in Forbes' 30 Under 30, Fortune's 40 Under 40 and is a Malaria No More "10 to END" innovator.